Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Amortization of Deferred Charges (2019 - 2024)

Historic Amortization of Deferred Charges for ImmunityBio (IBRX) over the last 4 years, with Q4 2024 value amounting to $5.0 million.

  • ImmunityBio's Amortization of Deferred Charges fell 2965.72% to $5.0 million in Q4 2024 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 7972.71%. This contributed to the annual value of $22.6 million for FY2024, which is 4672.37% down from last year.
  • Per ImmunityBio's latest filing, its Amortization of Deferred Charges stood at $5.0 million for Q4 2024, which was down 2965.72% from $6.2 million recorded in Q3 2024.
  • In the past 5 years, ImmunityBio's Amortization of Deferred Charges registered a high of $12.3 million during Q2 2023, and its lowest value of $370000.0 during Q1 2022.
  • For the 3-year period, ImmunityBio's Amortization of Deferred Charges averaged around $6.8 million, with its median value being $6.0 million (2024).
  • Per our database at Business Quant, ImmunityBio's Amortization of Deferred Charges skyrocketed by 301783.78% in 2023 and then plummeted by 5253.91% in 2024.
  • Quarter analysis of 3 years shows ImmunityBio's Amortization of Deferred Charges stood at $7.8 million in 2022, then fell by 8.2% to $7.1 million in 2023, then dropped by 29.66% to $5.0 million in 2024.
  • Its Amortization of Deferred Charges stands at $5.0 million for Q4 2024, versus $6.2 million for Q3 2024 and $5.8 million for Q2 2024.